Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

VRTX

Vertex Pharmaceuticals, Inc

Sep 12 • 04:00PM ET

394.53

-2.84 -0.71 %

Healthcare • Biotechnology • USA • NASD

Peers: BIIB GILD AMGN REGN MRNA INCY ALNY NBIX EXEL

| Held by: VTI VOO QQQ VUG SPY IVV XLV IWF VHT IBB

Scroll to Statements

Index	NDX, S&P 500	P/E	28.20	EPS (ttm)	13.99	Insider Own	0.32%	Shs Outstand	256.29M	Perf Week	-0.40%
Market Cap	101.15B	Forward P/E	19.16	EPS next Y	20.59	Insider Trans	1.37%	Shs Float	255.58M	Perf Month	-0.35%
Enterprise Value	96.29B	PEG	-	EPS next Q	4.60	Inst Own	96.27%	Short Float	1.42%	Perf Quarter	-14.24%
Income	3.64B	P/S	8.88	EPS this Y	4182.47%	Inst Trans	0.29%	Short Ratio	2.20	Perf Half Y	-21.55%
Sales	11.39B	P/B	5.89	EPS next Y	14.50%	ROA	16.47%	Short Interest	3.64M	Perf YTD	-2.03%
Book/sh	67.01	P/C	15.82	EPS next 5Y	-	ROE	22.77%	52W High	519.88 -24.11%	Perf Year	-16.20%
Cash/sh	24.93	P/FCF	28.90	EPS past 3/5Y	- -	ROIC	19.45%	52W Low	362.50 8.84%	Perf 3Y	38.70%
Dividend Est.	-	EV/EBITDA	20.92	Sales past 3/5Y	13.04% 21.61%	Gross Margin	86.08%	Volatility	1.74% 1.82%	Perf 5Y	48.04%
Dividend TTM	-	EV/Sales	8.45	EPS Y/Y TTM	847.05%	Oper. Margin	38.66%	ATR (14)	8.98	Perf 10Y	211.81%
Dividend Ex-Date	-	Quick Ratio	2.16	Sales Y/Y TTM	10.38%	Profit Margin	31.92%	RSI (14)	44.90	Recom	1.88
Dividend Gr. 3/5Y	- -	Current Ratio	2.52	EPS Q/Q	128.65%	SMA20	0.24%	Beta	0.43	Target Price	484.79
Payout	-	Debt/Eq	0.09	Sales Q/Q	13.33%	SMA50	-6.96%	Rel Volume	0.59	Prev Close	397.37
Employees	6100	LT Debt/Eq	0.09	Earnings	Aug 04 AMC	SMA200	-12.54%	Avg Volume	1.65M	Price	394.53
IPO	Jul 24, 1991	Option/Short	Yes / Yes	EPS/Sales Surpr.	5.80% 1.30%	Trades		Volume	977,946	Change	-0.71%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-03-25	Initiated	Raymond James	Mkt Perform
Aug-06-25	Upgrade	Wells Fargo	Equal Weight → Overweight	$460
May-07-25	Downgrade	Wolfe Research	Outperform → Peer Perform
May-06-25	Downgrade	Leerink Partners	Outperform → Market Perform	$503
Apr-22-25	Resumed	Cantor Fitzgerald	Overweight	$535
Feb-12-25	Upgrade	Canaccord Genuity	Sell → Hold	$408 → $424
Feb-11-25	Upgrade	Canaccord Genuity	Sell → Hold
Jan-30-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$460
Dec-20-24	Reiterated	H.C. Wainwright	Buy	$600 → $535
Dec-19-24	Downgrade	Oppenheimer	Outperform → Perform
Dec-09-24	Upgrade	Jefferies	Hold → Buy	$500 → $550
Nov-14-24	Initiated	Citigroup	Buy	$575
Oct-16-24	Initiated	Scotiabank	Sector Perform
Oct-10-24	Resumed	Raymond James	Mkt Perform
Aug-05-24	Downgrade	Barclays	Overweight → Equal Weight	$472 → $509
Jun-27-24	Initiated	Redburn Atlantic	Buy	$545
Apr-11-24	Upgrade	Evercore ISI	In-line → Outperform	$438
Feb-15-24	Initiated	Wolfe Research	Outperform	$515
Feb-06-24	Downgrade	Evercore ISI	Outperform → In-line	$436 → $438
Feb-02-24	Downgrade	Bernstein	Outperform → Mkt Perform

Show Previous Ratings

Sep-12-25 09:00AM	Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
07:30AM	3 Absurdly Cheap Stocks to Buy for the Long Haul (Motley Fool)
Sep-11-25 09:05AM	Vertex Scientists Awarded the 2025 Lasker~DeBakey Clinical Medical Research Award for Pioneering Discoveries in Cystic Fibrosis (Business Wire)
Sep-10-25 05:50PM	Vertex Pharmaceuticals (VRTX) Stock Slides as Market Rises: Facts to Know Before You Trade (Zacks)
Sep-08-25 08:35AM	Is Vertex Pharmaceuticals Stock Underperforming the S&P 500? (Barchart)
10:15AM	Loading…
Sep-04-25 10:15AM	Why This Biotech Company Could Be a Growth Stock Powerhouse (Motley Fool)
Sep-03-25 11:30AM	Why Is Vertex (VRTX) Up 6.9% Since Last Earnings Report? (Zacks)
08:17AM	Here's Why Vertex Pharmaceuticals (VRTX) is on Loomis Sayles Growth Fund's Detractors List (Insider Monkey)
Sep-02-25 09:25AM	Vertex Pharmaceuticals Incorporated (VRTX) Slid on Softer Revenue and Earnings (Insider Monkey)
Aug-31-25 08:53AM	August jobs report due out as Fed uncertainty looms: What to watch this week (Yahoo Finance)
08:40AM	Large-cap biotech is a sector to watch for investors: Analysts (Yahoo Finance)
06:45AM	3 No-Brainer Stocks to Buy Right Now (Motley Fool)
04:51AM	My 2 Favorite Stocks to Buy Right Now (Motley Fool)
Aug-29-25 10:22AM	Can CRSP's In Vivo Pipeline Aid Long-Term Growth Beyond Casgevy? (Zacks)
Aug-28-25 08:48AM	CRSP vs. BEAM: Which Gene Editing Stock Holds More Potential Right Now? (Zacks)
09:00AM	Loading…
Aug-27-25 09:00AM	Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Aug-25-25 02:57AM	Do Wall Street Analysts Like Vertex Pharmaceuticals Stock? (Barchart)
Aug-24-25 11:26AM	This Magnificent S&P 500 Dividend Stock Is Down 18% -- Time to Buy? (Motley Fool)
Aug-22-25 05:41AM	2 Beaten-Down Stocks With Incredible Upside Potential (Motley Fool)
Aug-21-25 11:15AM	CRISPR Therapeutics Gains 41.4% in 3 Months: How to Play the Stock (Zacks)
07:00AM	Why investors should buy Amphenol & avoid Vertex Pharmaceuticals (Yahoo Finance Video)
Aug-20-25 04:00PM	Vertex to Participate in Upcoming September Investor Conferences (Business Wire)
04:14AM	What's Wrong With Vertex Pharmaceuticals Stock? (Motley Fool)
Aug-18-25 11:15PM	Goldman Sachs Reiterated a Buy Rating on Vertex Pharmaceuticals (VRTX), Kept the PT Unchanged (Insider Monkey)
Aug-17-25 06:42AM	3 Fantastic Growth Stocks to Buy in August (Motley Fool)
Aug-15-25 09:10PM	Insiders Snap Up These 2 Stocks on the Dip Heres Why They Draw Plaudits from Goldman Sachs (TipRanks)
05:52PM	Vertex Pharma CEO Buys the Stock Dip (Barrons.com)
09:30AM	Is This Beaten-Down Stock a Buy on the Dip? (Motley Fool)
08:30AM	2 Growth Stocks That Are No-Brainer Buys Right Now (Motley Fool)
Aug-14-25 08:00AM	Vortex Energy Successfully Deploys ANT Sensors at Robinsons River Salt Project (GlobeNewswire)
09:00AM	Loading…
Aug-13-25 09:00AM	Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
07:30AM	[Latest] Global AI in Synthetic Biology Market Size/Share Worth USD 192.95 Billion by 2034 at a 28.63% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) (GlobeNewswire)
12:01AM	The 5 Most Interesting Analyst Questions From Vertex Pharmaceuticals's Q2 Earnings Call (StockStory)
Aug-12-25 11:53PM	VRTX Q2 2025 Deep Dive: New Product Launches and Pipeline Update in a Volatile Market (StockStory)
11:40AM	Can Rising Casgevy Sales Aid CRISPR Therapeutics Post Q2 Earnings? (Zacks)
Aug-11-25 11:00AM	Vertex Minerals to commence high-grade ore production at Reward gold mine (Mining Technology)
Aug-09-25 04:46AM	The Smartest Growth Stocks to Buy With $1,000 Right Now (Motley Fool)
Aug-08-25 06:45AM	5 Top Stocks to Buy in August (Motley Fool)
Aug-07-25 04:15PM	The RMR Group Announces $1.0 Billion Refinancing of Vertex Pharmaceuticals Headquarters in Boston Seaport District (Business Wire)
04:40AM	The Best Stocks to Invest $1,000 In Right Now (Motley Fool)
Aug-06-25 05:45PM	Analyst Report: Royalty Pharma plc (Morningstar Research)
03:24PM	Analyst Report: CRISPR Therapeutics AG (Morningstar Research)
12:23PM	Vertex Pharmaceuticals (VRTX) Hits New All-Time Low on Failed Clinical Trial (Insider Monkey)
09:36AM	Snap downgraded, Leidos upgraded: Wall Street's top analyst calls (The Fly)
06:10AM	S&P Futures Gain With Focus on Earnings and Fed Speak (Barchart)
05:36AM	Vertexs Journavx successor culled after falling short in Phase II trial (Clinical Trials Arena)
04:42AM	7 Reasons Why Vertex Pharmaceuticals Is a No-Brainer Stock to Buy on the Dip (Motley Fool)
Aug-05-25 07:12PM	Analyst Report: Vertex Pharmaceuticals Incorporated (Morningstar Research) -20.60%
05:15PM	Stocks to Watch Recap: Palantir, Coinbase, Gartner, Pfizer (The Wall Street Journal)
04:44PM	These Stocks Moved the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More (Barrons.com)
04:20PM	Why Vertex Pharma Is Feeling The Pain Despite A Second-Quarter Beat (Investor's Business Daily)
03:50PM	Why Vertex Pharmaceuticals (VRTX) Stock Is Trading Lower Today (StockStory)
02:27PM	Stocks to Watch Tuesday: Palantir, Hims, Pfizer, TSMC (The Wall Street Journal)
02:17PM	These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More (Barrons.com)
01:00PM	VRTX: Vertex Shares Tank After Pain Drug Flop in Key Trial (GuruFocus.com)
11:54AM	CRSP Stock Down on Huge Q2 Loss, Focus on Increasing Casgevy Adoption (Zacks)
11:38AM	Top Stock Movers Now: Gartner, Axon Enterprise, Palantir, and More (Investopedia)
11:33AM	VRTX Q2 Earnings Beat, Stock Down as Pain Drug Misses Study Goal (Zacks)
09:52AM	Vertex Pharmaceutical Stock Dives as Firm to Stop Developing Acute Pain Drug (Investopedia)
09:41AM	Vertex Pharmaceuticals, Kyndryl, Caterpillar: Trending Tickers (Yahoo Finance Video)
08:47AM	Stock Market Today: Dow Rises Ahead Of Key Data; Palantir Surges On Earnings (Live Coverage) (Investor's Business Daily)
08:00AM	Vortex Energy Mobilizes Field Crews for ANT Survey at Robinsons River Salt Project (GlobeNewswire)
07:36AM	5 Things to Know Before the Stock Market Opens (Investopedia)
06:18AM	Vertex Stock Tumbles 15% After Strong Earnings. What's Spooking Investors. (Barrons.com)
06:13AM	US stock futures higher amid mixed corporate earnings (USA TODAY)
05:49AM	Palantir shares hit new record after earnings, and other early market movers (MarketWatch)
05:08AM	These Stocks Moved the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More (Barrons.com)
03:03AM	Vertex Pharmaceuticals Inc (VRTX) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Aug-04-25 06:18PM	Selloff? What Selloff? Monday Market Rebound (Zacks)
05:48PM	Stocks to Watch Monday: Palantir, Hims & Hers, Vertex, Tesla (The Wall Street Journal)
05:35PM	Vertex Crashes After Pain Drug Flop Outweighs Second-Quarter Beat (Investor's Business Daily)
05:30PM	Compared to Estimates, Vertex (VRTX) Q2 Earnings: A Look at Key Metrics (Zacks)
05:19PM	Vertex Pharmaceuticals reports earnings, beating EPS, revenue estimates (CNBC TV)
05:15PM	Vertex Pharmaceuticals (VRTX) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
05:13PM	Vertex Stock Falls After Pain-Drug Setback, Despite Stronger Earnings (The Wall Street Journal)
04:21PM	Vertex Pharmaceuticals's (NASDAQ:VRTX) Q2 Sales Beat Estimates But Stock Drops 13.5% (StockStory)
04:16PM	Vertex: Q2 Earnings Snapshot (Associated Press Finance)
04:15PM	CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results (GlobeNewswire)
04:01PM	Vertex Reports Second Quarter 2025 Financial Results (Business Wire)
04:01PM	Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain (Business Wire)
Aug-02-25 11:02PM	What To Expect From Vertex Pharmaceuticals's (VRTX) Q2 Earnings (StockStory)
06:45AM	3 Unstoppable Stocks to Buy in August (Motley Fool)
Aug-01-25 04:38PM	McDonalds, Palantir, Novo Nordisk Earnings: What to Watch Next Week (The Wall Street Journal)
01:14PM	KBRA Assigns Preliminary Ratings to VRTX 2025-HQ (Business Wire)
06:30AM	2 Top Stocks I Wouldn't Hesitate to Invest $1,000 in Right Now (Motley Fool)
Jul-30-25 09:15AM	Stay Ahead of the Game With Vertex (VRTX) Q2 Earnings: Wall Street's Insights on Key Metrics (Zacks)
Jul-29-25 05:50PM	Vertex Pharmaceuticals (VRTX) Ascends While Market Falls: Some Facts to Note (Zacks)
10:00AM	Harmony Biosciences Holdings, Inc. (HRMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
09:14AM	Vertex Gears Up to Report Q2 Earnings: Is a Beat in the Cards? (Zacks)
09:00AM	Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know (Zacks)
07:04AM	LEAD3R Launches 2025 Healthy Team Summit, Sponsored by The Future of Teamwork Podcast (PR Newswire)
Jul-28-25 10:36AM	CRISPR Therapeutics to Report Q2 Earnings: What's in the Cards? (Zacks)
10:00AM	Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
07:15AM	The 3 Things That Matter for Vertex Pharmaceuticals Now (Motley Fool)
12:04AM	Vertex Pharmaceuticals (VRTX): Buy, Sell, or Hold Post Q1 Earnings? (StockStory)
Jul-25-25 10:40PM	Vertex Pharmaceuticals Incorporated (VRTX) Launches JOURNAVX, First Non-Opioid Acute Pain Treatment (Insider Monkey)
09:58AM	REGN Q2 Earnings: Will Higher Dupixent Profits Fuel Growth? (Zacks)
Jul-23-25 05:50PM	Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts (Zacks)
05:06PM	Top Stock Reports for Wells Fargo, Abbott & American Express (Zacks)
09:57AM	Zai Lab Limited (ZLAB) Stock Jumps 6.8%: Will It Continue to Soar? (Zacks)

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bhatia Sangeeta N.	Director	Aug 27 '25	Sale	386.69	266	102,860	4,565	Aug 29 04:02 PM
Bhatia Sangeeta N.	Director	Aug 27 '25	Proposed Sale	386.69	266	102,860		Aug 27 09:38 AM
Kewalramani Reshma	CEO & President	Aug 06 '25	Buy	389.58	10,000	3,895,768	115,968	Aug 07 04:23 PM
SACHS BRUCE I	Director	Aug 06 '25	Buy	389.68	5,000	1,948,416	45,000	Aug 07 04:19 PM
LR 2019 Benefit Trust	Director	May 21 '25	Proposed Sale	447.18	170	76,021		May 21 04:58 PM
SR 2019 Benefit Trust	Director	May 21 '25	Proposed Sale	447.18	170	76,021		May 21 04:58 PM
ALTSHULER DAVID	EVP, Chief Scientific Officer	May 15 '25	Sale	424.69	52	22,084	23,281	May 19 05:07 PM
ALTSHULER DAVID	Officer	May 15 '25	Proposed Sale	424.69	52	22,084		May 15 10:36 AM
Bhatia Sangeeta N.	Director	May 02 '25	Sale	505.86	400	202,344	4,831	May 05 04:14 PM
Bhatia Sangeeta N.	Director	May 02 '25	Proposed Sale	505.86	400	202,344		May 02 09:47 AM
ALTSHULER DAVID	EVP, Chief Scientific Officer	Mar 13 '25	Sale	510.00	3,231	1,647,810	23,281	Mar 17 04:09 PM
ALTSHULER DAVID	Officer	Mar 13 '25	Proposed Sale	510.00	3,231	1,647,810		Mar 13 11:10 AM
WAGNER CHARLES F JR	EVP & Chief Financial Officer	Mar 10 '25	Sale	500.00	3,298	1,649,000	51,671	Mar 12 04:11 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Mar 10 '25	Sale	499.99	3,242	1,620,968	51,239	Mar 12 04:10 PM
ALTSHULER DAVID	EVP, Chief Scientific Officer	Mar 10 '25	Sale	500.00	3,231	1,615,500	26,512	Mar 12 04:08 PM
Tatsis Ourania	Officer	Mar 10 '25	Proposed Sale	499.99	3,242	1,620,968		Mar 10 01:58 PM
WAGNER CHARLES F JR	Officer	Mar 10 '25	Proposed Sale	500.00	3,298	1,649,000		Mar 10 01:02 PM
ALTSHULER DAVID	Officer	Mar 10 '25	Proposed Sale	500.00	3,231	1,615,500		Mar 10 12:42 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Mar 04 '25	Sale	485.49	4,058	1,970,118	54,481	Mar 06 04:08 PM
ALTSHULER DAVID	EVP, Chief Scientific Officer	Mar 03 '25	Sale	490.00	3,231	1,583,190	29,743	Mar 05 04:08 PM
Tatsis Ourania	Officer	Mar 04 '25	Proposed Sale	485.49	4,058	1,970,118		Mar 04 01:39 PM
ALTSHULER DAVID	Officer	Mar 03 '25	Proposed Sale	490.00	3,231	1,583,190		Mar 03 04:17 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Feb 27 '25	Sale	475.34	530	251,930	58,539	Feb 28 04:48 PM
Atkinson Edward Morrow III	EVP, Chief Technical Ops. Off.	Feb 27 '25	Sale	475.34	2,650	1,259,651	19,352	Feb 28 04:36 PM
ALTSHULER DAVID	EVP, Chief Scientific Officer	Feb 27 '25	Sale	480.00	1,272	610,560	32,974	Feb 28 04:23 PM
ALTSHULER DAVID	Officer	Feb 27 '25	Proposed Sale	480.00	1,272	610,560		Feb 27 11:20 AM
Atkinson Edward Morrow III	Officer	Feb 27 '25	Proposed Sale	475.34	2,650	1,259,651		Feb 27 10:18 AM
Tatsis Ourania	Officer	Feb 27 '25	Proposed Sale	475.34	530	251,930		Feb 27 10:14 AM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Feb 25 '25	Sale	480.95	354	170,256	64,031	Feb 26 04:15 PM
Atkinson Edward Morrow III	EVP, Chief Technical Ops. Off.	Feb 25 '25	Sale	480.95	1,767	849,839	24,484	Feb 26 04:09 PM
Ambrose Kristen	SVP & Chief Accounting Officer	Feb 25 '25	Sale	480.95	884	425,160	9,086	Feb 26 04:06 PM
ALTSHULER DAVID	EVP, Chief Scientific Officer	Feb 25 '25	Sale	480.95	848	407,846	40,200	Feb 26 04:04 PM
Tatsis Ourania	Officer	Feb 25 '25	Proposed Sale	480.95	354	170,256		Feb 25 11:38 AM
ALTSHULER DAVID	Officer	Feb 25 '25	Proposed Sale	480.95	848	407,846		Feb 25 11:13 AM
Atkinson Edward Morrow III	Officer	Feb 25 '25	Proposed Sale	480.95	1,767	849,839		Feb 25 10:59 AM
ALTSHULER DAVID	EVP, Chief Scientific Officer	Feb 20 '25	Sale	480.00	1,111	533,280	45,019	Feb 24 04:07 PM
ALTSHULER DAVID	Officer	Feb 20 '25	Proposed Sale	480.00	1,111	533,280		Feb 20 03:45 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Feb 18 '25	Sale	455.06	244	111,035	67,695	Feb 19 04:36 PM
Biller Jonathan	EVP and Chief Legal Officer	Feb 18 '25	Sale	455.06	1,657	754,034	17,606	Feb 19 04:28 PM
Ambrose Kristen	SVP & Chief Accounting Officer	Feb 18 '25	Sale	455.06	671	305,345	10,798	Feb 19 04:21 PM
Tatsis Ourania	Officer	Feb 18 '25	Proposed Sale	455.06	244	111,035		Feb 18 11:34 AM
Biller Jonathan	Officer	Feb 18 '25	Proposed Sale	455.06	1,657	754,034		Feb 18 11:29 AM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Feb 11 '25	Sale	459.83	310	142,547	64,021	Feb 12 04:50 PM
Biller Jonathan	EVP and Chief Legal Officer	Feb 11 '25	Sale	459.87	3,433	1,578,734	16,330	Feb 12 04:36 PM
Atkinson Edward Morrow III	EVP, Chief Technical Ops. Off.	Feb 11 '25	Sale	459.83	1,747	803,323	23,225	Feb 12 04:29 PM
Ambrose Kristen	SVP & Chief Accounting Officer	Feb 11 '25	Sale	459.83	1,376	632,726	9,953	Feb 12 04:24 PM
Biller Jonathan	Officer	Feb 11 '25	Proposed Sale	459.87	3,433	1,578,744		Feb 11 11:57 AM
Tatsis Ourania	Officer	Feb 11 '25	Proposed Sale	459.83	310	142,547		Feb 11 11:05 AM
Atkinson Edward Morrow III	Officer	Feb 11 '25	Proposed Sale	459.83	1,747	803,323		Feb 11 09:49 AM
ALTSHULER DAVID	EVP, Chief Scientific Officer	Nov 15 '24	Sale	478.56	15	7,178	25,813	Nov 19 04:08 PM
ALTSHULER DAVID	Officer	Nov 15 '24	Proposed Sale	478.56	15	7,178		Nov 15 10:31 AM
WAGNER CHARLES F JR	EVP & Chief Financial Officer	Nov 11 '24	Sale	518.27	3,000	1,554,810	44,137	Nov 13 04:15 PM
Kewalramani Reshma	CEO & President	Nov 08 '24	Sale	515.00	15,198	7,826,970	75,772	Nov 12 04:08 PM
Kewalramani Reshma	Officer	Nov 08 '24	Proposed Sale	515.00	15,198	7,826,970		Nov 08 02:58 PM
Biller Jonathan	EVP and Chief Legal Officer	Oct 02 '24	Sale	461.66	999	461,198	16,651	Oct 03 04:12 PM
Biller Jonathan	Officer	Oct 02 '24	Proposed Sale	461.66	999	461,198		Oct 02 10:04 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VRTX

Vertex Pharmaceuticals, Inc

Upgrade your FINVIZ experience